Zacks Investment Research on MSN
Analysts estimate Medifast (MED) to report a decline in earnings: What to look out for
Medifast (MED) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...
Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely ...
Medifast, Inc. MED is likely to register a decrease in both top and bottom lines when it reports first-quarter 2025 earnings on April 28, after market close. The Zacks Consensus Estimate for ...
Medifast enjoyed record profits immediately after the pandemic. The emergence of GLP-1 medications has driven revenue, income, and the number of active Optavia coaches down. Management has laid out a ...
Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 ...
Baltimore-based Medifast opened a research and development hub in Owings Mills on Tuesday with plans to develop new products and expand from weight management into the larger $230 billion health and ...
BALTIMORE, June 1, 2023 /PRNewswire/ -- Medifast, the company behind the health and wellness community OPTA VIA®, today announced further strategic changes to enhance its Fuel for the Future program, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The latest layoffs come after ...
Company’s Clinical Heritage and Leadership in Metabolic Health Highlighted Through Poster Presentations and Expert Contributions Medifast, the health and wellness company known for its science-backed, ...
Medifast (NYSE: MED), the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended September 30, 2025 ...
Medifast is a growth company that is sporting some attractive value-stock metrics after its shares have fallen to a level that is “simply ridiculous” when measured against its prospects, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results